col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

60 Results       Page 1

Wiley: Clinical and Translational Science
  original article Date Title Authors   All Authors
1 [GO] 2023―Apr―29 A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations Claire Steinbronn, Yashpal S. Chhonker, Jenell Stewart, Hannah Leingang, Kate B. Heller, Meighan L. Krows, et al. (+11)
2 [GO] 2023―Mar―17 Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID -19 Rebecca N. Bauer, Anastasia Teterina, Haridha Shivram, Jacqueline McBride, Carrie M. Rosenberger, Fang Cai, et al. (+10)
3 [GO] 2022―Nov―30 Training and cultivating the translational science workforce: Responses of Clinical and Translational Science Awards program hubs to the COVID -19 pandemic Miriam A. Bredella, Boris B. Volkov, Jamie M. Doyle
4 [GO] 2022―Nov―04 The vaccine hesitancy continuum among hesitant adopters of the COVID-19 vaccine Ramey Moore, Rachel S. Purvis, Don E. Willis, Kyle C. Worley, Devonte Hervey, Sharon Reece, et al. (+2)
5 [GO] 2022―Aug―05 A Review of Clinical Efficacy Data Supporting Emergency Use Authorization for COVID -19 Therapeutics and Lessons for Future Pandemics Seo-Hyun Yoo, Lauren Kim, Michelle Lu, Kira Nagoshi, Mark N. Namchuk
6 [GO] 2022―Feb―25 Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients Susan Trümpelmann, Andreas Schulte-Mecklenbeck, Olga V. Steinberg, Timo Wirth, Manfred Fobker, Lisa Lohmann, et al. (+4)
7 [GO] 2022―Feb―09 A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting Nathan Stasko, Adam S. Cockrell, Jacob F. Kocher, Ibrahim Henson, David Emerson, Ye Wang, et al. (+7)
8 [GO] 2022―Jan―14 The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19 Alexander P. J. Vlaar, Endry H. T. Lim, Sanne Bruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, et al. (+6)
9 [GO] 2021―Dec―25 Chasing the storm: Recruiting non-hospitalized patients for a multi-site randomized controlled trial in the United States during the COVID-19 pandemic Kelly Hu, Jean-Claude Tardif, Melanie Huber, Maria Daly, Aisha T. Langford, Ruth Kirby, et al. (+6)
10 [GO] 2021―Nov―19 Response to “Wearable Remote Monitoring and COVID-19 Elena S. Izmailova, Theodore F. Reiss
11 [GO] 2021―Nov―18 Wearable remote monitoring and COVID-19 Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
12 [GO] 2021―Nov―11 Exploration for the Effect of Renal Function and Renal Replacement Therapy on Pharmacokinetics of Remdesivir and GS-441524 in Patients with COVID-19: A Limited Case Series Pyoeng Gyun Choe, Sae Im Jeong, Chang Kyung Kang, Liju Yang, SeungHwan Lee, Joo-Youn Cho, et al. (+6)
13 [GO] 2021―Nov―07 Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID-19 pandemic Jing Zhu, Gauri Rao, Paul M. Armistead, Jonathan Ptachcinski, Daniel L. Weiner, Tim Wiltshire, Daniel J. Crona
14 [GO] 2021―Oct―21 Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial Susanne H. Hodgson, Poppy Iveson, Jessica Larwood, Sophie Roche, Hazel Morrison, Catherine Cosgrove, et al. (+14)
15 [GO] 2021―Sep―28 Evidence-time dilemma in a pandemic with high mortality: Can outcome-driven decision making on vaccines prevent deaths? Klaus Eckhardt
16 [GO] 2021―Jul―28 Phase 1 study in healthy participants to evaluate safety, tolerability and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19 Nathan D. Pfeifer, Arthur Lo, David L. Bourdet, Kenneth Colley, Dave Singh
17 [GO] 2021―Jul―14 Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation Johan L. Plas, Michiel J. Esdonk, Ingrid M. C. Kamerling, Adam F. Cohen
18 [GO] 2021―Jul―02 COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear Don E. Willis, Jennifer A. Andersen, Keneshia Bryant-Moore, James P. Selig, Christopher R. Long, Holly C. Felix, et al. (+2)
19 [GO] 2021―Jun―14 Immune-Viral Dynamics Modeling for SARS-CoV-2 Drug Development Youfang Cao, Wei Gao, Luzelena Caro, Julie A. Stone
20 [GO] 2021―Jun―03 Closer to the Patient Means Better Decisions: Wearable Remote Monitoring of Patients with COVID-19 Lung Disease Elena S. Izmailova, Theodore F. Reiss
21 [GO] 2021―May―31 Potential benefit of vitamin d supplementation in people with respiratory illnesses, during the Covid-19 pandemic Vasudevan V. Chetty, Manoranjenni Chetty
22 [GO] 2021―May―13 A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19 Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida, Jiro Mukai, Kenji Furukawa, Seitaro Ohtsu, et al. (+4)
23 [GO] 2021―May―02 Autoantibodies in moderate and critical cases of COVID-19 Soon Hee Chang, Dohsik Minn, Yu Kyung Kim
24 [GO] 2021―Apr―09 COVID-19 vaccines and treatments: When speed is necessary and not enough Thaddeus H. Grasela, David A. Price, John A. Wagner
25 [GO] 2021―Mar―31 Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients’ Drug Regimens: A Drug Safety Simulation Study Matt K. Smith, Ravil Bikmetov, Sweilem B. Al Rihani, Malavika Deodhar, Matthew Hafermann, Pamela Dow, et al. (+2)
26 [GO] 2021―Mar―26 Assessing the Impact of COVID-19 on Registered Interventional Clinical Trials Nour Hawila, Arthur Berg
27 [GO] 2021―Feb―23 Applying the CiPA Approach to Evaluate Cardiac Proarrhythmia Risk of some Antimalarials Used Off-label in the First Wave of COVID-19 Annie Delaunois, Matthew Abernathy, Warren D. Anderson, Kylie A. Beattie, Khuram W. Chaudhary, Julie Coulot, et al. (+14)
28 [GO] 2021―Feb―19 Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Zakariya Kashour, Tarek Kashour, Danielle Gerberi, Imad M. Tleyjeh
29 [GO] 2021―Feb―19 Virtual Screening FDA Approved Drugs against Multiple Targets of SARS-CoV-2 Hualou Liang, Liang Zhao, Xiajing Gong, Meng Hu, Hongbin Wang
30 [GO] 2021―Jan―08 Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell Seyed Fazel Nabavi, Solomon Habtemariam, Ioana Berindan-Neagoe, Cosmin Andrei Cismaru, Dedmer Schaafsma, Saeid Ghavami, et al. (+3)
31 [GO] 2021―Jan―07 Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19. A simulation study Jun-ichi Okada, Takashi Yoshinaga, Takumi Washio, Kohei Sawada, Seiryo Sugiura, Toshiaki Hisada
32 [GO] 2021―Jan―07 Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2 James M. Gallo
33 [GO] 2020―Dec―13 The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics Uttara Soumyanarayanan, Mimi Choong, James Leong, Murray M. Lumpkin, Guido Rasi, John H. Skerritt, et al. (+2)
34 [GO] 2020―Dec―11 SARS-CoV-2 Infection as a trigger of autoimmune response Maria C. Sacchi, Stefania Tamiazzo, Paolo Stobbione, Lisa Agatea, Piera De Gaspari, Anna Stecca, et al. (+5)
35 [GO] 2020―Nov―17 Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule Kunyi Wu, Kimberly L. Bergman
36 [GO] 2020―Nov―02 A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Pre-clinical Pharmacokinetic Study Tien-Tzu Tai, Tzung-Ju Wu, Huey-Dong Wu, Yi-Chen Tsai, Hui-Ting Wang, An-Min Wang, et al. (+2)
37 [GO] 2020―Oct―21 Projected utility of pharmacogenomic testing among individuals hospitalized with COVID-19: A retrospective multicenter study in the United States James M. Stevenson, G. Caleb Alexander, Natasha Palamuttam, Hemalkumar B. Mehta
38 [GO] 2020―Sep―29 COVID-19 and immunological dysregulation: can autoantibodies be useful? Simona Pascolini, Antonio Vannini, Gaia Deleonardi, Michele Ciordinik, Annamaria Sensoli, Ilaria Carletti, et al. (+16)
39 [GO] 2020―Sep―29 COVID-19 and venous thromboembolism in intensive care or medical ward Giampiero Avruscio, Giuseppe Camporese, Elena Campello, Enrico Bernardi, Paolo Persona, Christian Passarella, et al. (+8)
40 [GO] 2020―Sep―28 Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic Serena Romani, Alexandre Gérard, Audrey Fresse, Delphine Viard, Élise Van-Obberghen, Joëlle Micallef, et al. (+2)
41 [GO] 2020―Sep―24 Association Between Prescribed Ibuprofen and Severe COVID-19 Infection: A Nationwide Register-Based Cohort Study Kristian Kragholm, Thomas A. Gerds, Emil Fosbøl, Mikkel Porsborg Andersen, Matthew Phelps, Jawad H. Butt, et al. (+7)
42 [GO] 2020―Sep―24 Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics Rajesh Krishna
43 [GO] 2020―Sep―21 Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report Yongchao Gao, Tao Liu, Weijun Zhong, Rong Liu, Honghao Zhou, Weihua Huang, Wei Zhang
44 [GO] 2020―Sep―16 Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19) Pablo Zubiaur, Dora Koller, Miriam Saiz-Rodríguez, Marcos Navares-Gómez, Francisco Abad-Santos
45 [GO] 2020―Sep―16 Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients. Marinella Lauriola, Arianna Pani, Giovanbattista Ippoliti, Andrea Mortara, Stefano Milighetti, Marjieh Mazen, et al. (+4)
46 [GO] 2020―Sep―16 Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, et al. (+20)
47 [GO] 2020―Sep―05 Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs Veronique Michaud, Pamela Dow, Sweilem B. Al Rihani, Malavika Deodhar, Meghan Arwood, Brian Cicali, Jacques Turgeon
48 [GO] 2020―Sep―03 The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study Chen Shi, Cong Wang, Hanxiang Wang, Chao Yang, Fei Cai, Fang Zeng, et al. (+7)
49 [GO] 2020―Sep―03 Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-label Randomized Controlled Pilot Study Ting Li, Laifang Sun, Wenwu Zhang, Chanfan Zheng, Chenchen Jiang, Mingjing Chen, et al. (+4)
50 [GO] 2020―Aug―31 An Evaluation of Biometric Monitoring Technologies for Vital Signs in the Era of Covid-19 Christine Manta, Sneha S. Jain, Andrea Coravos, Dena Mendelsohn, Elena S. Izmailova
51 [GO] 2020―Aug―16 Effect of common medications on the expression of SARS-CoV-2 entry receptors in kidney tissue Narjes Saheb Sharif-Askari, Fatemeh Saheb Sharif-Askari, Mashael Alabed, Ahmad Abou Tayoun, Tom Loney, Mohammed Uddin, et al. (+7)
52 [GO] 2020―Jun―27 Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects Rita Humeniuk, Anita Mathias, Huyen Cao, Anu Osinusi, Gong Shen, Estelle Chng, et al. (+3)
53 [GO] 2020―Jun―11 Remote monitoring in clinical trials during the COVID-19 pandemic Elena S. Izmailova, Robert Ellis, Christopher Benko
54 [GO] 2020―May―31 Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19 Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, et al. (+3)
55 [GO] 2020―May―31 Testing for SARS-CoV-2: the day the world turned its attention to the clinical laboratory Xuemei Zhao, Julia F. Markensohn, David A. Wollensak, Omar F. Laterza
56 [GO] 2020―May―22 Time to step up: A call to action for the clinical and quantitative pharmacology community to accelerate therapeutics for COVID-19 Dan Hartman, Steven Kern, Fran Brown, Suzanne K. Minton, Craig R. Rayner
57 [GO] 2020―May―18 Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19 Christopher J Morabito, Bagirath Gangadharan
58 [GO] 2020―Apr―21 Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19 Yaqing Zhou, Tao Han, Jiaxin Chen, Can Hou, Lei Hua, Shu He, et al. (+12)
59 [GO] 2020―Apr―08 Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection Samuel LM Arnold, Frederick Buckner
60 [GO] 2020―Mar―25 Optimizing COVID-19 candidate therapeutics: Thinking Without Borders Craig R. Rayner, Patrick F Smith, Kevin Hershberger, David Wesche

60 Results       Page 1


Last change 2023―Apr―13 19:50:14 UTC

© Daten-Quadrat 2022       Done in 0.010 sec